New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg, overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg, overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Iżrael - Ingliż - Ministry of Health

medici medical ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 0.5 g / 10 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott aldrich syndromemyeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.children with congenital aids and recurrent infections.immunomodulation :idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.guillain barré syndrome.kawasaki disease.allogeneic bone marrow transplantation

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 5 g / 100 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents in:- primary immunodeficiency syndromes with impaired antibody production - hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed- hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation- congenital aids with recurrent bacterial infectionsimmunomodulation in adults, and children and adolescents in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease

Malta - Ingliż - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 0.550 g/l - immune sera and immunoglobulins

Malta - Ingliż - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg/ml - immune sera and immunoglobulins

Malta - Ingliż - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg/ml - immune sera and immunoglobulins

Malta - Ingliż - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg/ml - immune sera and immunoglobulins